Device Industry Attorneys Criticize FDA's Emerging Signals Draft Guidance
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's 'emerging signals' draft guidance, released Dec. 31, is drawing criticism from medical device industry lawyers and advocates who complain it will unfairly cast a negative light on some medtech products, will lower beneficial use of devices and provide fodder for product liability suits.